New combo therapy targets stomach cancer lymph nodes
NCT ID NCT07007182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread only to nearby lymph nodes. About 54 participants will receive either standard chemo or a more intensive plan including chemo, surgery, and radiation. The goal is to see if the combined approach helps control the disease longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SOX regimen (oxaliplatin plus S-1) or CAPEOX regimen (oxaliplatin plus capecitabine), with or without a PD-1 inhibitor
What this could lead to
If successful, this could offer a more effective treatment plan for gastric cancer patients with lymph node spread, potentially improving survival and disease control.
What could go wrong
This is a small, early-phase trial with only 54 participants, so results may not apply to all patients. The added treatments also carry risks like side effects from chemo and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••